Veraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading as of today on the Nasdaq under the ticker symbol VRXA. For the company, which has roots in the Heidelberg region, the move marks its transition from a research-driven company to a publicly listed biotech developer.
London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
French immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to up to €19.3m in gross proceeds over 24 months.
Can in‑space manufacturing help cancer patients take complex medicines at home? For a technology that aims to do just that, UK‑based BioOrbit has just raised £9.8m (around €11.3m) – the “world’s largest” seed round of for in‑space manufacturing.
Valneva SE, the French specialty‑vaccine developer, has completed an €84m reserved offering, adding a useful cash buffer just as the group enters a high‑risk window for its Lyme disease and shigellosis‑vaccine candidates.
Belgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune disease
A newly launched Finnish deep-tech company has cracked the code for single-molecule protein detection. VTT-originated Proteins.1 has launched with €4.7m in pre-seed funding, aiming to stop the deadliest diseases before symptoms even appear.
Copenhagen-based biotech Adcendo ApS has closed an oversubscribed US$75 million Series C round led by Jeito Capital. The funds will fuel early-phase trials of three ADC candidates for cancers with high unmet need.
Clean Food Group has secured £4.5 million from a group of investors led by Clean Growth Fund and New Agrarian, together with £700,000 in non-dilutive funding from Innovate UK. The London-based biotech will use the funds to accelerate the ramp-up of the world’s largest yeast-based oils and fats facility in Knowsley, Liverpool.
The European Investment Fund has launched a new fund of funds with a target volume of €15 billion to strengthen growth financing in Europe’s technology sector. The programme is considered the largest of its kind in Europe to date and is aimed at around 100 late-stage venture capital funds.
Planet Volumes via Unsplash+
Valneva
A. C. via Unsplash+
Proteins.1
Adcendo ApS
Pic by Susan Wilkinson via Unsplash
123rf.com/Paul Grecaud